<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 8: management of cerebrospinal fluid shunt infection.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tamber MS, Klimo P Jr, Mazzola CA, Flannery AM. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 8: Management of cerebrospinal fluid shunt infection. J Neurosurg Pediatr. 2014 Nov;14 Suppl 1:60-71. [37 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25988784&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The rating schemes used for the strength of the evidence (&lt;strong&gt;Class I-III&lt;/strong&gt;) and the levels of recommendations (&lt;strong&gt;Level I-III&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Supplementation of antibiotic treatment with partial (externalization) or with complete shunt hardware removal is an option in the management of cerebrospinal fluid (CSF) shunt infection. &lt;strong&gt;Strength of Recommendation: Level II, moderate degree of clinical certainty&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence to recommend either shunt externalization or complete shunt removal as a preferred surgical strategy for the management of CSF shunt infection. Therefore, clinical judgment is required. &lt;strong&gt;Strength of Recommendation: Level III, unclear degree of clinical certainty&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence to recommend the combination of intrathecal and systemic antibiotics for patients with CSF shunt infection in whom the infected shunt hardware cannot be fully removed or must be removed and immediately replaced, or when the CSF shunt infection is caused by specific organisms. The potential neurotoxicity of intrathecal antibiotic therapy may limit its routine use. &lt;strong&gt;Strength of Recommendation: Level III, unclear degree of clinical certainty&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for Primary Research Question&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence for Primary Research Question&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;8%&quot; valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Therapeutic Studies: Investigating the Results of Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Prognostic Studies: Investigating the Effect of a Patient Characteristic on the Outcome of Disease&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Diagnostic Studies: Investigating a Diagnostic Test&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Economic and Decision Analyses: Developing an Economic or Decision Model&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I RCTs (and study results were homogenous&lt;sup&gt;3&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality prospective study&lt;sup&gt;4&lt;/sup&gt; (all patients were enrolled at the same point in their disease with &amp;ge;80% follow-up of enrolled patients) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality RCT (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prospective&lt;sup&gt;4&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies or Class I studies with inconsistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Untreated controls from an RCT &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality prospective study (e.g., patients enrolled at different points in their disease or &amp;lt;80% follow-up) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Study of nonconsecutive patients; without consistently applied &quot;gold&quot; standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Analyses based on limited alternatives and costs; and poor estimates &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series&lt;sup&gt;8&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Poor reference standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Analyses with no sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;RCT = randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;A combination of results from two or more prior studies.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Studies provided consistent results.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Study was started before the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;The study was started after the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Patients identified for the study based on their outcome, called &quot;cases&quot; (e.g., failed total arthroplasty) are compared to those who did not have outcome, called &quot;controls&quot; (e.g., successful total hip arthroplasty).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;Patients treated one way with no comparison group of patients treated in another way.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of the Recommendations Rating Scheme&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force used methodologies endorsed by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Guidelines Committee to assign a strength category to each recommendation in this review. Linking evidence to recommendations through the use of evidentiary tables has been endorsed by the American Medical Association, the AANS, and the CNS. This process validates and supports the relationship between the strength of evidence and the strength of recommendations. Demonstrating the highest degree of clinical certainty, Class I evidence is used to support recommendations of the strongest type, defined as Level I recommendations. Level II recommendations reflect a moderate degree of clinical certainty and are supported by Class II evidence or a strong consensus of Class III evidence. Level III recommendations denote clinical uncertainty, which is supported by inconclusive or conflicting evidence or expert opinion.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pediatric hydrocephalus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cerebrospinal fluid (CSF) shunt infection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Neurological Surgery" />
      <FieldValue Value="Neurology" />
      <FieldValue Value="Pediatrics" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Physician Assistants" />
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To answer the following question: What is the optimal treatment strategy for cerebrospinal fluid (CSF) shunt infection in pediatric patients with hydrocephalus?&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Pediatric patients with hydrocephalus and cerebrospinal fluid (CSF) shunt infection&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Supplementation of systemic antibiotic treatment using partial (externalization) or complete shunt hardware removal&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following interventions were considered but there was insufficient evidence to recommend:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li class=&quot;Note&quot;&gt;Shunt externalization or complete shunt removal &lt;/li&gt;&#xD;&#xA;    &lt;li class=&quot;Note&quot;&gt;Combination of intrathecal and systemic antibiotics &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cerebrospinal fluid (CSF) shunt infection rates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reinfection rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Length of hospital stay &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cure rates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;General Search Strategy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Literature Search&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force worked with a research librarian and methodologist to assist with the formulation of search terms and strategies used to search the US National Library of Medicine PubMed/MEDLINE database and the Cochrane Database of Systematic Reviews for relevant literature published between January 1966 and March 2012.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Four to five Task Force members used the article inclusion/exclusion criteria described below to screen abstracts and provide a list of relevant articles for a full-text review. Each Task Force member was blinded to the lists of abstracts provided by others. Staff compiled all lists together for review and final approval by all Task Force members.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The searches were supplemented with manual screenings of bibliographies from all retrieved articles. In addition, the bibliographies of potentially relevant systematic reviews were screened for potentially relevant articles. All literature identified either by searches of the electronic database or by manual searches were subject to the article inclusion/exclusion criteria listed below. Specific search strategies used by Task Force members are provided below.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Article Inclusion/Exclusion Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Articles were retrieved and included as evidence to support the topics discussed in this review if they met specific inclusion/exclusion criteria. These criteria were also applied to articles provided by Task Force members who supplemented the electronic database searches with articles obtained from manual searches of bibliographies from the original articles. To reduce bias, the criteria were specified before conducting the literature searches. For the purposes of the systematic review and guidelines, articles that did not meet the following criteria were &lt;em&gt;not&lt;/em&gt; deemed evidence and were not considered as potential evidence to support the topics and clinical recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To be included in the review, an article had to meet the following criteria:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Studies that combined results in patients (younger than 18 years of age) who had congenital and acquired hydrocephalus with results in patients with &quot;normal&quot; pressure hydrocephalus were excluded if the study enrolled fewer than 80% of the target patient population. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies that enrolled mixed patient populations were included only if separate results were reported for the target population. The results of the target population were the only results considered as evidence to support the recommendations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study was a full article report of a clinical study. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study was not a meeting abstract, editorial, letter, or a commentary. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prospective case series had to report baseline values. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Case series studies with nonconsecutive enrollment of patients were excluded. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies had to have appeared in a peer-reviewed publication or a registry report. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies had to enroll at least 10 patients for each distinct outcome that was measured. If a comparative study, a minimum enrollment of five patients per treatment arm for each outcome was necessary. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study involved humans. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study was published in or after 1966. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study presented results quantitatively. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study did not involve &quot;in vitro&quot; or &quot;biomechanical&quot; data or results obtained in cadavers. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study was published in English. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Papers reporting the results of systematic reviews, meta-analyses, or guidelines developed by others were excluded. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Articles presenting systematic reviews or meta-analyses conducted by others, as well as guidelines developed by others, were not included as evidence to support this review due to differences in inclusion/exclusion criteria between those specified in such articles and those established by the Task Force. Although such articles were not included as evidence to support the review, they were recalled for full-text review so that the Task Force could conduct manual searches of the articles' bibliographies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Specific Search Strategy for This Guideline&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force searched the US National Library of Medicine (PubMed/MEDLINE) database and the Cochrane Database of Systematic Reviews for the period January 1966 through March 2012 using the following medical subject headings (MeSH): (CSF shunts) AND (bacterial infection OR prosthesis-related infection OR catheter-related infection) AND (treatment OR outcome) AND (antibacterial agents OR injections OR antibiotics OR device removal OR ventriculostomy OR combined modality therapy). Searches were limited to studies in patients younger than 18 years of age, the management of initial (not repeat) cerebrospinal fluid (CSF) shunt infection, and to the English language.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search Results&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 342 abstracts were screened and 69 full-text articles were retrieved for review. An examination of the reference lists of these 69 full-text articles yielded an additional 24 articles that warranted full-text review (see Fig. 2 in the original guideline document). Subsequent review of the full texts of these 93 articles led to the exclusion of 66 articles based on predefined criteria, leaving 27 articles as the basis for the evidentiary tables for this particular recommendation. Reasons for exclusion of full-text articles included the following: literature review (n=19); no treatment outcomes given (n=14); pediatric patients not reported separately (n=6); wrong target population (n=1); small sample size (n=19); not a full report of a clinical study (n=2); not relevant to the study question (n=3); and other (n=2).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Twenty-seven articles were the basis for the evidentiary tables for this particular recommendation (see Tables 1-4 in the original guideline document).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Levels of Evidence for Primary Research Question&lt;/span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence for Primary Research Question&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;8%&quot; valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Therapeutic Studies: Investigating the Results of Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Prognostic Studies: Investigating the Effect of a Patient Characteristic on the Outcome of Disease&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Diagnostic Studies: Investigating a Diagnostic Test&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Economic and Decision Analyses: Developing an Economic or Decision Model&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I RCTs (and study results were homogenous&lt;sup&gt;3&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality prospective study&lt;sup&gt;4&lt;/sup&gt; (all patients were enrolled at the same point in their disease with &amp;ge;80% follow-up of enrolled patients) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality RCT (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prospective&lt;sup&gt;4&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies or Class I studies with inconsistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Untreated controls from an RCT &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality prospective study (e.g., patients enrolled at different points in their disease or &amp;lt;80% follow-up) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Study of nonconsecutive patients; without consistently applied &quot;gold&quot; standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Class III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Analyses based on limited alternatives and costs; and poor estimates &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Class III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series&lt;sup&gt;8&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Poor reference standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Analyses with no sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;RCT = randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;A combination of results from two or more prior studies.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Studies provided consistent results.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Study was started before the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;The study was started after the first patient enrolled.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Patients identified for the study based on their outcome, called &quot;cases&quot; (e.g., failed total arthroplasty) are compared to those who did not have outcome, called &quot;controls&quot; (e.g., successful total hip arthroplasty).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;8&lt;/sup&gt;Patients treated one way with no comparison group of patients treated in another way.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The quality of evidence was rated using an evidence hierarchy developed by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Guidelines Committee for each of the four different study types: therapeutic, diagnostic, prognostic, and clinical assessment (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Studies meeting the inclusion criteria were selected and graded according to their quality of evidence (Classes I&amp;ndash;III) (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field). Evidentiary tables (Tables 1-4 in the original guideline document) were constructed that summarized pertinent study results, and based on the quality of the literature, recommendations were made. See Fig. 1 in the original guideline for a flowchart showing the organization of evidentiary tables based on alternative paradigms for the management of cerebrospinal fluid (CSF) shunt infection.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus (Nominal Group Technique)" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations contained in this guideline deliberately eschew the use of expert opinion, relying strictly on information available in the literature. Studies have reported that expert opinions may not use evaluable evidence, if the papers containing that evidence do not support the &quot;expert&quot; point of view. Throughout the development of these guidelines, the Task Force used evidence-based methodologies and adhered to strict criteria that had been defined a priori as specified by the Institute of Medicine's standards for conducting systematic reviews and clinical evidence-based guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This effort was begun by a small study group that convened at the Pediatric Section Annual Meeting in Austin, Texas, in 2011. At that time the basic topics were considered, and over the course of several months these were further refined. Members of the Task Force involved in the creation of this document were recruited from a variety of institutions and subspecialty disciplines in an effort to have as broad a representation of opinions and expertise as possible.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force followed protocols established by the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS). A conscientious effort was also made to be sure that conflict of interest was avoided. Members who had published extensively in certain areas were mindfully assigned to evaluate evidence in other topics. Every effort was made to ensure that the work product would be transparent and trustworthy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Methods&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Process Overview&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force and the Pediatric Section of the AANS/CNS conducted a systematic review of the literature relevant to the management of hydrocephalus in infants and children. Additional details of the systematic review are provided below. During the development process, the panel participated in a series of conference calls and meetings. Multiple iterations of the written review were conducted by individuals in the Task Force and various AANS/CNS committees.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Selection of Clinical Topics&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The goals of this effort were to discern the most effective strategies for a variety of hydrocephalus-related problems, including acquired hydrocephalus of the premature neonate. The Task Force also considered the use of technical adjuvants such as antibiotic-impregnated catheters, endoscopic placement of shunt catheters, electromagnetic guidance for shunt catheter placement, and ultrasound guidance for shunt catheter placement. It was hoped that these adjuvants would lead to improvements in outcome and a reduction in the frequency of revision.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Complications associated with ventriculoperitoneal shunts and endoscopic third ventriculostomies are known, and these interventions' effects and long-term successes are useful to evaluate. Complications associated with infection are of particular significance. Therefore, the prevention and treatment of infection occupies a significant portion of the hydrocephalus literature. Finally, the correlation of ventricle size to outcome in a child is a source of great interest as an indicator of the success of the intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following the identification of hydrocephalus-related problems, the Task Force developed preliminary recommendations that were formatted similarly to the PICO (patients, interventions, comparisons, and outcomes) formula to aid in the determination of the overall scope of the review and the terminology used to formulate the literature search strategies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Voting on the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force used a structured voting technique to finalize and approve the final recommendations, language, and strength of the recommendations presented in this review. The voting technique is referred to as the &quot;nominal group technique.&quot; This technique includes up to 3 rounds of voting using secret ballots to ensure that each Task Force member is blinded to the responses of other Task Force members. All the recommendations in this review were approved following the first round of voting and no further discussion was needed to finalize the recommendations. During the course of editing and finalizing the document, changes were made to allow recommendations to conform to the rules of evidence and language as described earlier. When this occurred, the changes were reviewed and approved by the group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Fig. 1 in the methodology document (see the &quot;Availability of Companion Documents&quot; field) for an outline of the key steps in the process of developing these clinical practice guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Strength of the Recommendations Rating Scheme&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force used methodologies endorsed by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Guidelines Committee to assign a strength category to each recommendation in this review. Linking evidence to recommendations through the use of evidentiary tables has been endorsed by the American Medical Association, the AANS, and the CNS. This process validates and supports the relationship between the strength of evidence and the strength of recommendations. Demonstrating the highest degree of clinical certainty, Class I evidence is used to support recommendations of the strongest type, defined as Level I recommendations. Level II recommendations reflect a moderate degree of clinical certainty and are supported by Class II evidence or a strong consensus of Class III evidence. Level III recommendations denote clinical uncertainty, which is supported by inconclusive or conflicting evidence or expert opinion.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Guideline Panel Consensus and Practice Guideline Approval Process&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Topic subtask forces were created from the larger Task Force. Each subtask force took part in the literature selection, review of the literature, creation of the evidence tables, and creation and editing of the final review. The final draft review was then circulated to the entire Task Force for feedback, discussion, and, ultimately, approval.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following Task Force approval, the completed systematic review was presented to the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) for consideration and recommendation of endorsement on behalf of the CNS Executive Committee and the AANS Board of Directors. As part of the evaluation process, the JGC reviewers could provide input on the content and methodologies used to create the systematic review.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The successful treatment of cerebrospinal fluid (CSF) shunt infection aims to cure the infection (that is, minimize the probability of reinfection or relapse) while maintaining functional CSF diversion and minimizing morbidity, mortality, and the cost of therapy.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The potential neurotoxicity of intrathecal antibiotic therapy may limit its routine use.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This clinical systematic review of and evidence-based guidelines for the treatment of pediatric hydrocephalus were developed by a physician volunteer task force. The articles contained therein are provided as an educational tool based on an assessment of current scientific and clinical information as well as accepted approaches to treatment. They are not intended to be a fixed protocol because some patients may require more or less treatment. Patient care and treatment should always be based on a clinician's independent medical judgment given individual clinical circumstances. The information in the guidelines reflects the current state of knowledge at the time of the project's completion. The presentations are designed to provide an accurate review of the subject matter that is covered. These guidelines are disseminated with the understanding that the recommendations of the authors and consultants who have collaborated in their development are not meant to replace individualized care and treatment advice from patients' physicians. If medical advice or assistance is required, the services of a competent physician should be sought. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of each patient's particular situation and on the basis of existing resources. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In general, the methodological quality of the evidence related to the recommendations was poor. The studies that met the inclusion criteria were typically descriptive series of small numbers of patients and were vulnerable to the biases and limitations of a retrospective study design. Because the studies relied on the accuracy and completeness of the medical record, the control of potentially confounding variables was nonexistent. Although most studies did compare outcomes between patient groups treated under alternative management protocols, the rationale behind why a particular treatment was assigned to a particular patient group was not clearly described, leading to significant issues with selection bias. For those studies describing the outcomes of a single management protocol, between-study comparisons of results was hampered by widely disparate management protocols and the use of nonuniform outcome measures (and definitions thereof). These limitations precluded, for the most part, any meaningful quantitative synthesis of the data; what is presented in the guideline is a largely qualitative review of the evidence relevant to this recommendation. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Resources" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tamber MS, Klimo P Jr, Mazzola CA, Flannery AM. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 8: Management of cerebrospinal fluid shunt infection. J Neurosurg Pediatr. 2014 Nov;14 Suppl 1:60-71. [37 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25988784&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2014 Nov" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="American Association of Neurological Surgeons - Medical Specialty Society" />
      <FieldValue Value="Congress of Neurological Surgeons - Professional Association" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The systematic review and evidence-based guidelines were funded exclusively by the Congress of Neurological Surgeons (CNS) and American Association of Neurological Surgeons (AANS) Pediatric Section, which received no funding from outside commercial sources to support the development of this document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Development of this review was editorially independent from the funding agencies. The funding agencies' review of these guideline papers, following Joint Guidelines Committee (JGC) approval but prior to submission for publication, was limited to whether to endorse or reject the body of work.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Mandeep S. Tamber, MD, PhD, Department of Pediatric Neurological Surgery, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania; Paul Klimo Jr., MD, MPH, Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Le Bonheur Children's Hospital, Memphis, Tennessee; Catherine A. Mazzola, MD, Division of Pediatric Neurological Surgery, Goryeb Children's Hospital, Morristown, New Jersey; Ann Marie Flannery, MD, Department of Neurological Surgery, Saint Louis University, St. Louis, Missouri&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Conflict(s) of Interest &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;None. All members of the Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force declared any potential conflicts of interest prior to beginning work on this evidence review.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;http://thejns.org/doi/pdf/10.3171/2014.7.PEDS14328&quot; title=&quot;Journal of Neurosurgery: Pediatrics Web site&quot;&gt;Journal of Neurosurgery: Pediatrics Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Flannery AM, Mazzola CA, Klimo P Jr, Duhaime AC, Baird LC, Tamber MS, Limbrick DD Jr, Nikas DC, Kemp J, Post AF, Auguste KI, Choudhri AF, Mitchell LS, Buffa D. Foreword: pediatric hydrocephalus: systematic literature review and evidence-based guidelines. J Neurosurg Pediatr; 2014 Nov;14 Suppl 1:1-2. Available from the &lt;a href=&quot;http://thejns.org/doi/pdf/10.3171/2014.8.PEDS14426&quot; title=&quot;Journal of Neurosurgery: Pediatrics Web site&quot;&gt;Journal of Neurosurgery: Pediatrics Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Flannery AM, Mitchell L. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 1: introduction and methodology. J Neurosurg Pediatr; 2014 Nov;14 Suppl 1:3-7. Available from the &lt;a href=&quot;http://thejns.org/doi/pdf/10.3171/2014.7.PEDS14321&quot; title=&quot;Journal of Neurosurgery: Pediatrics Web site&quot;&gt;Journal of Neurosurgery: Pediatrics Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;JNS pediatrics supplement: pediatric hydrocephalus systematic literature review and evidence-based guidelines. Podcast. 2014 Nov 1. Available from the &lt;a href=&quot;http://thejns.org/action/showNews?type=podcast&quot; title=&quot;Journal of Neurosurgery Web site&quot;&gt;Journal of Neurosurgery Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Guideline development methodology: endorsed by the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the AANS/CNS Joint Guideline Committee. 2012 Feb. 12 p. Available from the &lt;a href=&quot;https://www.cns.org/sites/default/files/jgcguidelinedevelopmentmethodology.pdf&quot; title=&quot;Congress of Neurological Surgeons Web site&quot;&gt;Congress of Neurological Surgeons Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on September 17, 2015. The information was not verified by the guideline developer. &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>